ADXS Advaxis, Inc.

8.11
-0.12  -1.46%
Previous Close 8.23
Open 8.17
Price To book 2.76
Market Cap 325.59M
Shares 40,147,000
Volume 755,447
Short Ratio 14.16
Av. Daily Volume 731,990

SEC filingsSee all SEC filings

  1. 8-K - Current report 17515880
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17515735
  3. 8-K - Current report 162053981
  4. 8-K - Current report 161947643
  5. 8-K - Current report 161916142

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac
Cervical cancer
Phase 1/2 updated data due 2H 2017.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Phase 3 initiation announced October 2016. Enrollment update at ASCO June 2017.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac - GOG 0265 study
Cervical cancer
Phase 1b ongoing.
ADXS-HER2
HER2-driven malignancies - cancer
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac
Anal cancer (FAWCETT)

Latest News

  1. Advaxis, Inc. – Value Analysis (NASDAQ:ADXS) : January 13, 2017
  2. ADVAXIS, INC. Financials
  3. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : January 12, 2017
  4. ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
  5. Advaxis Provides 2017 Business Outlook
  6. ADVAXIS, INC. Files SEC form 10-K, Annual Report
  7. ADVAXIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  8. Discussion on Advaxis’ ADXS-NEO, ADXS-HOT Programs Held During the International Congress on Immunotherapies in Cancer
  9. Advaxis to Present Data at ImVacS-Immunization and Vaccine Summit on Use of Detoxified Listeriolysin O (dtLLO) as an Effective Adjuvant in Vaccine Formulations
  10. How Advaxis, Inc. (ADXS) Stacks Up Against Its Peers
  11. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : November 22, 2016
  12. INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc.
  13. Advaxis to Present at the Jefferies 2016 London Healthcare Conference
  14. ETF’s with exposure to Advaxis, Inc. : November 11, 2016
  15. Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
  16. Advaxis, Inc. breached its 50 day moving average in a Bullish Manner : ADXS-US : November 10, 2016
  17. Lifshitz & Miller Law Firm Announces Investigation of Advaxis, Inc., Banc of California, Inc., Biogen Inc., Franklin Resources, Inc., Juniper Pharmaceuticals, Inc., Opus Bank, Taro Pharmaceutical Industries Ltd., and Tyson Foods, Inc.
  18. Advaxis Cervical Cancer Drug Makes Progress (ADXS)
  19. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by the Board of Advaxis, Inc. - ADXS
  20. ADVAXIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Filings

  1. 8-K - Current report 17515880
  2. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17515735
  3. 8-K - Current report 162053981
  4. 8-K - Current report 161947643
  5. 8-K - Current report 161916142
  6. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161880391
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161874595
  8. 8-K - Current report 161847778
  9. CT ORDER - Confidential treatment order 161847736
  10. 424B5 - Prospectus [Rule 424(b)(5)] 161839477